These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29089310)

  • 1. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.
    Battistella M; Leboeuf C; Ram-Wolff C; Hurabielle C; Bonnafous C; Sicard H; Bensussan A; Bagot M; Janin A
    Blood; 2017 Dec; 130(26):2900-2902. PubMed ID: 29089310
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-KIR3DL2 therapy in the treatment of Sézary syndrome.
    Quaglino P
    Lancet Oncol; 2019 Aug; 20(8):1048-1049. PubMed ID: 31253571
    [No Abstract]   [Full Text] [Related]  

  • 3. KIR3DL2 in cutaneous T-cell lymphoma: from a promising biomarker to a potential therapeutic target.
    Sun J; Wang Y
    Br J Dermatol; 2020 Jun; 182(6):1325-1326. PubMed ID: 31808144
    [No Abstract]   [Full Text] [Related]  

  • 4. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
    Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
    Nikolova M; Bagot M; Boumsell L; Bensussan A
    Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.
    Hurabielle C; Leboeuf C; Ram-Wolff C; Meignin V; Rivet J; Vignon-Pennamen MD; Bonnafous C; Sicard H; Fite C; Raffoux E; Arnulf B; Oksenhendler E; Sicre de Fontbrune F; Peffault de Latour R; Socié G; Bouaziz JD; Lebbé C; Bensussan A; Janin A; Bagot M; Battistella M
    Br J Dermatol; 2018 Jul; 179(1):197-199. PubMed ID: 29315492
    [No Abstract]   [Full Text] [Related]  

  • 7. KIR3DL2/CpG ODN interaction mediates Sézary syndrome malignant T cell apoptosis.
    Ghazi B; Thonnart N; Bagot M; Bensussan A; Marie-Cardine A
    J Invest Dermatol; 2015 Jan; 135(1):229-237. PubMed ID: 25007046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome.
    Hurabielle C; Thonnart N; Ram-Wolff C; Sicard H; Bensussan A; Bagot M; Marie-Cardine A
    Clin Cancer Res; 2017 Jul; 23(14):3619-3627. PubMed ID: 28119365
    [No Abstract]   [Full Text] [Related]  

  • 9. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma with KIR3DL2 and NKp46 expression in a human immunodeficiency virus carrier.
    Karkouche R; Ingen-Housz-Oro S; Le Gouvello S; Charlotte F; Thomas M; Zehou O; Frenkel V; Boutboul D; Chosidow O; Caumes E; Gaulard P; Ortonne N
    J Cutan Pathol; 2015 Mar; 42(3):199-205. PubMed ID: 25407699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIR3DL2 is a coinhibitory receptor on Sézary syndrome malignant T cells that promotes resistance to activation-induced cell death.
    Thonnart N; Caudron A; Legaz I; Bagot M; Bensussan A; Marie-Cardine A
    Blood; 2014 Nov; 124(22):3330-2. PubMed ID: 25414436
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity.
    Roelens M; Delord M; Ram-Wolff C; Marie-Cardine A; Alberdi A; Maki G; Homyrda L; Bensussan A; Bagot M; Toubert A; Moins-Teisserenc H
    Blood; 2017 Sep; 130(12):1468-1471. PubMed ID: 28760889
    [No Abstract]   [Full Text] [Related]  

  • 13. CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides.
    Ortonne N; Le Gouvello S; Tabak R; Marie-Cardine A; Setiao J; Berrehar F; Nghe-Tang A; Martin N; Bagot M; Bensussan A
    Exp Dermatol; 2012 Jun; 21(6):461-3. PubMed ID: 22621189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New developments in Sézary syndrome].
    Caudron A; Marie-Cardine A; Bensussan A; Bagot M
    Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
    Wobser M; Goebeler M
    Hautarzt; 2019 Oct; 70(10):815-830. PubMed ID: 31511903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.
    Van Der Weyden C; Bagot M; Neeson P; Darcy PK; Prince HM
    Expert Opin Investig Drugs; 2018 Aug; 27(8):691-697. PubMed ID: 30001170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
    Decroos A; Cheminant M; Bruneau J; Carras S; Parinet V; Pelletier L; Lacroix L; Martin N; Giustiniani J; Lhermitte L; Asnafi V; Battistella M; Lemonnier F; De Leval L; Sicard H; Bonnafous C; Gauthier L; Genestier L; Caruso S; Gaulard P; Hermine O; Ortonne N
    Haematologica; 2023 Oct; 108(10):2830-2836. PubMed ID: 37165836
    [No Abstract]   [Full Text] [Related]  

  • 19. Folliculotropic Sézary syndrome: a new variant of cutaneous T-cell lymphoma.
    Gerami P; Guitart J
    Br J Dermatol; 2007 Apr; 156(4):781-3. PubMed ID: 17286634
    [No Abstract]   [Full Text] [Related]  

  • 20. Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma.
    Blom A; Beylot-Barry M; D'Incan M; Laroche L
    J Am Acad Dermatol; 2011 Aug; 65(2):404-410. PubMed ID: 21550694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.